Skip to main content

Table 2 Incidence of primary endpoints in rheumatoid arthritis patients assigned to PPSV23 or placebo

From: The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial

  Vaccine group (n = 464)   Placebo group (n = 436)   
Incidence rate per 1000 patient-years (n) 95% CI Incidence rate per 1000 patient-years (n) 95% CI P value
Pneumococcal pneumonia 2.6 (2) 0.7–9.5 1.4 (1) 0.3–8.0 0.523
Nonpneumococcal pneumonia 19.6 (15) 11.9–32.3 19.9 (14) 11.9–33.4 0.985
All-cause pneumonia 22.2 (17) 13.9–35.6 21.3 (15) 12.9–35.2 0.856
  1. PPSV23 23-valent pneumococcal polysaccharide vaccine, CI confidence interval